Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 5, 2008, Pages

  Awumey, Emmanuel M ^a   Hill, Sylvie K ^a   Diz, Debra I ^b   Bukoski, Richard D ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Arachidonic acid; Ca2+ sensing receptor; Vasorelaxation

Indexed keywords

1,6 HEXAMETHYLENEDICARBAMIC ACID BIS(CYCLOHEXANONE OXIME) ESTER; 2 ARACHIDONOYLGLYCEROL; ARACHIDONYL TRIFLUOROMETHYL KETONE; CALCIUM; CALCIUM SENSING RECEPTOR; CANNABINOID RECEPTOR; CYTOCHROME P450; EPOXYICOSATRIENOIC ACID; IBERIOTOXIN; LIPOPROTEIN LIPASE; MEPACRINE; MICONAZOLE; PHENYLEPHRINE; PHOSPHOLIPASE A2; RIMONABANT; 2-ARACHIDONYLGLYCEROL; ACETYLCHOLINE; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; ARACHIDONYLTRIFLUOROMETHANE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CANNABINOID 1 RECEPTOR; DIHOMO GAMMA LINOLENIC ACID; ENZYME INHIBITOR; PEPTIDE; PIPERIDINE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; PYRAZOLE DERIVATIVE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTERY DILATATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; RESISTANCE BLOOD VESSEL; VASCULAR ENDOTHELIUM; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; MALE; METABOLISM; SIGNAL TRANSDUCTION; VASODILATATION; WISTAR RAT;

8,11,14-EICOSATRIENOIC ACID; ACETYLCHOLINE; ANIMALS; ARACHIDONIC ACIDS; CALCIUM; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLYCERIDES; LIPOPROTEIN LIPASE; MALE; MESENTERIC ARTERIES; MICONAZOLE; PEPTIDES; PHENYLEPHRINE; PHOSPHOLIPASES A2; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PYRAZOLES; QUINACRINE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CALCIUM-SENSING; SIGNAL TRANSDUCTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 44949177557     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01042.2007     Document Type: Article

References (66)

1. Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G. Effects of the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-natriuresis relationship. Hypertension 42: 8-13, 2003.
2. Angus JA, Wright CE. Techniques to study the pharmacodynamics of isolated large and small blood vessels. J Pharmacol Toxicol Methods 44: 395-407, 2000.
3. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336: 1117-1124, 1997.
4. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension. A scientific statement from the American Heart Association. Hypertension 47: 296-308, 2006.
5. Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, Platonov M, Koshal A, Hashimoto K, Campbell WB, Falck JR, Michelakis ED. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BKCa channels. Circulation 107: 769-776, 2003.
6. 2+-sensing receptor stably expressed in HEK293 cells. Am J Physiol Cell Physiol 292: C1895-C1905, 2007.
7. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81: 239-297, 2001.
8. 2+ receptor and blood pressure regulation: a hypothesis. Am J Hypertens 11: 1117-1123, 1998.
9. 2+-induced relaxation of isolated arteries. Hypertension 30: 1431-1439, 1997.
10. 2+ with vascular tone. Nephrol Dial Transplant 16: 218-221, 2001.
11. 1 receptor-deficient mice. Hypertension 39: 251-260, 2002.
12. Campbell WB, Harder DR. Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84: 484-488, 1999.
13. Campbell WB, Holmes BB, Falck JR, Capdevila JH, Gauthier KM. Regulation of potassium channels in coronary smooth muscle by adenoviral expression of cytochrome P-450 epoxygenase. Am J Physiol Heart Circ Physiol 290: H64-H71, 2006.
14. Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 49: 590-596, 2007.
15. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41: 163-181, 2000.
16. Capdevila JH, Falck JR. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophys Res Commun 285: 571-576, 2001.
17. Capdevila JH, Falck JR, Imig JD. Roles of the cytochrome P450 arachidonic monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int 72: 683-689, 2007.
18. Chu ZM, Croft KD, Kingsbury DA, Falck JR, Reddy KM, Beilin LJ. Cytochrome P450 metabolites of arachidonic acid may be important mediators in angiotensin II-induced vasoconstriction in the rat mesentery in vivo. Clin Sci (Lond) 98: 277-282, 2000.
19. DeLozier TC, Tsao CC, Coulter SJ, Foley J, Bradbury JA, Zeldin DC, Goldstein JA. CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther 310: 845-854, 2004.
20. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99: 10819-10824, 2002.
21. Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 66: 1260-1264, 2004.
22. Earley S, Pastszyn A, Walker BR. Cytochrome P-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. Am J Physiol Heart Circ Physiol 285: H127-H136, 2003.
23. Fleming I. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Trends Cardiovasc Med 10: 166-170, 2000.
24. Fleming I. Cytochrome P450 enzymes in vascular homeostasis. Circ Res 89: 753-762, 2001.
25. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res 49: 525-533, 2004.
26. Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A. Evidence against a role of cytochrome P450-derived arachidonic acid metabolites in endothelium-dependent hyperpolarization by acetylcholine in rat isolated mesenteric artery. Br J Pharmacol 120: 439-446, 1997.
27. Gauthier KM, Baewer DV, Hittner S, Hillard CJ, Nithipatikom K, Reddy DS, Falck JR, Campbell WB. Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. Am J Physiol Heart Circ Physiol 288: H1344-H1351, 2005.
28. Ghisdal P, Vandenberg G, Hamaide M, Wibo M, Morel N. The diacylglycerol lipase inhibitor RHC-80267 potentiates the relaxation to acetylcholine in rat mesenteric artery by anticholinesterase action. Eur J Pharmacol 517: 92-102, 2005.
29. Gordon GR, Mulligan SJ, MacVicar BA. Astrocyte control of the cerebrovasculature. Glia 55: 1214-1221, 2007.
30. Halpern W, Mulvany MJ, Warshaw DM. Mechanical properties of smooth muscle cells in the walls of arterial resistance vessels. J Physiol 275: 85-101, 1978.
31. Hatton DC, Scrogin KE, Metz JA, McCarron DA. Dietary calcium alters blood pressure reactivity in spontaneously hypertensive rats. Hypertension 13: 622-629, 1989.
32. Hatton DC, McCarron DA. Dietary calcium and blood pressure in experimental models of hypertension. A review. Hypertension 23: 513-530, 1994.
33. Hao CM, Breyer MD. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 71: 1105-1115, 2007.
34. Holla VR, Makita K, Zaphiropoulos PG, Capdevila JH. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest 104: 751-760, 1999.
35. Iliff JJ, Close LN, Selden NR, Alkayed NJ. A novel role for P450 eicosanoids in the neurogenic control of cerebral blood flow in the rat. Exp Physiol 92: 653-658.
36. 2+-induced relaxation. J Pharmacol Exp Ther 289: 245-250, 1999.
37. Iwai N, Inagami T. Isolation of preferentially expressed genes in the kidneys of hypertensive rats. Hypertension 17: 161-169, 1991.
38. Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D. A key role for diacylglycerol lipase- in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol 72: 612-621, 2007.
39. Koehler RC, Gebremedhin D, Harder DR. Role of astrocytes in cerebrovascular regulation. J Appl Physiol 100: 307-317, 2006.
40. Kotchen TA, Ott CE, Whitescarver SA, Resnick LM, Gertner JM, Blehschmidt NG. Calcium and calcium regulating hormones in the "prehypertensive" Dahl salt sensitive rat (calcium and salt sensitive hypertension). Am J Hypertens 2: 747-753, 1989.
41. Leung D, Saghatelian A, Simon GM, Cravatt BF. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45: 4720-4726, 2006.
42. Liu J, Batkai S, Pacher P, Harvey-White J, Wagner JA, Cravatt BF, Kunos G. Activation of anandamide synthesis in mouse macrophages and its role in endotoxin-induced hypotension. J Biol Chem 278: 45034-45039, 2003.
43. Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, Chan AC, Zhou Z, Huang BX, Kim HY, Kunos G. A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 103: 13345-13350, 2006.
44. Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, Razdan RJ, Kunos G. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54: 1-7, 2008.
45. Makita K, Takahashi K, Karara A, Jacobson HR, Falck JR, Capdevilla JH. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 94: 2412-2420, 1994.
46. Makita K, Falck HR, Capdevilla JH. Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system. FASEB J 10: 1456-1463, 1996.
47. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88, 2003.
48. McCarron DA. Calcium metabolism and hypertension. Kidney Int 35: 717-736, 1989.
49. McCarron DA, Reusser ME. Finding consensus in the dietary calcium-blood pressure debate. J Am Coll Nutr 18: 398S-405S, 1999.
50. Muntzel MS, Hatton DC, Metz JA, McCarron DA. Dietary calcium alters blood pressure in neonatal spontaneously hypertensive rats. Am J Hypertens 2: 158-162, 1989.
51. 2+-induced relaxation of isolated mesenteric resistance arteries. Am J Physiol Heart Circ Physiol 274: H1655-H1661, 1998.
52. Ohanian J, Gatfield KM, Ward DT, Ohanian V. Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol 288: H1756-H1762, 2005.
53. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R, Falck JR, Capdevila JH. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 280: 27138-27146, 2006.
54. Ralevic V. Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. Eur J Pharmacol 472: 1-21, 2003.
55. Reusser ME, McCarron DA. Reducing hypertensive cardiovascular disease risk of African Americans with diet: focus on the facts. J Nutr 136: 1099-1102, 2006.
56. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185, 2002.
57. Sacks FM, Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A dietary approach to prevent hypertension: a review of the Dietary Approaches to Stop Hypertension (DASH) Study. Clin Cardiol 22: III6-III10, 1999.
58. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Borgel J, Mugge A, Lindpaintner K, Huesing A, Maisch B, Zeldin DC, Liao JK. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110: 2132-2136, 2004.
59. Straub SV, Bonev AD, Wilkerson MK, Nelson MT. Dynamic inositol trisphosphate-mediated calcium signals within astrocytic endfeet underlie vasodilation of cerebral arterioles. J Gen Physiol 128: 659-669, 2006.
60. Su P, Kaushal KM, Kroetz DL. Inhibition of renal AA ω-hydroxylase activity with ABT reduces blood pressure in the SHR. Am J Physiol Regul Integr Comp Physiol 275: R426-R428, 1998.
61. Tang X, Edwards EM, Holmes BB, Falck JR, Campbell WB. Role of phospholipase C and diacylglyceride lipase pathway in arachidonic acid release and acetylcholine-induced vascular relaxation in rabbit aorta. Am J Physiol Heart Circ Physiol 290: H37-H45, 2006.
62. 2+ receptor in rat arteries. Br J Pharmacol 125: 1397-1404, 1998.
63. 2+-induced relaxation of isolated arteries. Life Sci 64: 887-894, 1999.
64. Wang MH, Guan H, Nguyen X, Zand BA, Nasjletti A, Laniado-Schwartzman M. Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatraenoic acid synthesis in rat kidneys. Am J Physiol Renal Physiol 276: F246-F253, 1999.
65. Ca channels. Am J Physiol Heart Circ Physiol 280: H2430-H2440, 2001.
66. Zhao X, Imig JD. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 4: 73-84, 2003.